{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT03275350",
      "orgStudyIdInfo": {
        "id": "CTN-0067",
        "type": "NIH"
      },
      "secondaryIdInfos": [
        {
          "id": "UG1DA015815",
          "type": "NIH",
          "domain": "National Institute on Drug Abuse"
        },
        {
          "id": "UG1DA013732",
          "type": "NIH",
          "domain": "National Institute on Drug Abuse"
        }
      ],
      "organization": {
        "fullName": "National Institute on Drug Abuse",
        "class": "NIH"
      },
      "briefTitle": "CHOICES Scale-Up Study",
      "officialTitle": "Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-up study",
      "acronym": "CHOICES"
    },
    "descriptionModule": {
      "briefSummary": "This qualitative sub-study of the CHOICES trial assessed the experiences of participants with HIV and opioid use disorder (OUD) who were randomized to extended-release naltrexone (XR-NTX). The study aimed to identify facilitators and barriers to successful XR-NTX induction through semi-structured interviews with participants who either successfully completed or failed to complete the induction process.",
      "detailedDescription": "The CHOICES study (Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study) randomized participants with HIV and opioid use disorder (OUD) to HIV clinic-based extended-release naltrexone (XR-NTX) versus treatment-as-usual (buprenorphine or methadone). Because XR-NTX requires a complete cessation of opioids prior to initiation (induction), this process presents significant barriers. This qualitative analysis involved semi-structured interviews with a convenience sample of 37 participants (20 who completed induction, 17 who did not) across five HIV clinics between 2018 and 2019. Interviews were recorded, transcribed, and analyzed using Thematic Analysis to identify themes related to the induction experience. Key findings explored readiness for change, the role of supportive environments and comfort medications during withdrawal, staff interactions, anxiety regarding withdrawal symptoms, ambivalence toward stopping opioid use, and perceptions of XR-NTX effects versus agonist therapies."
    },
    "conditionsModule": {
      "conditions": [
        "Opioid Use Disorder",
        "HIV Infections"
      ],
      "keywords": [
        "Extended-Release Naltrexone",
        "Opioid Use Disorder",
        "HIV",
        "Induction",
        "Opioid Withdrawal",
        "Qualitative Research",
        "Buprenorphine",
        "Methadone"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "patientRegistry": false,
      "phases": [
        "NA"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "interventionModelDescription": "Participants with HIV and opioid use disorder (OUD) were randomized to HIV clinic-based extended-release naltrexone (XR-NTX) versus treatment-as-usual (i.e., buprenorphine, methadone).",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE",
          "maskingDescription": "Participants were randomized to either opioid agonist therapy or opioid antagonist therapy (injection versus oral/sublingual standard of care), implying an open-label design."
        }
      },
      "enrollmentInfo": {
        "count": 37,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Extended-release naltrexone (XR-NTX)",
          "type": "EXPERIMENTAL",
          "description": "Participants randomized to receive HIV clinic-based extended-release naltrexone (XR-NTX). This treatment requires complete cessation of opioid use prior to induction.",
          "interventionNames": [
            "Drug: Extended-release naltrexone"
          ]
        },
        {
          "label": "Treatment-as-usual (TAU)",
          "type": "ACTIVE_COMPARATOR",
          "description": "Participants randomized to receive treatment-as-usual, consisting of opioid agonist therapy (i.e., buprenorphine, methadone).",
          "interventionNames": [
            "Drug: Treatment-as-usual (Buprenorphine or Methadone)"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Extended-release naltrexone",
          "description": "A deep muscle injection of an opioid antagonist that lasts 28 days and eliminates the need for daily dosing. Requires an opioid-free state several days prior to initiation.",
          "armGroupLabels": [
            "Extended-release naltrexone (XR-NTX)"
          ]
        },
        {
          "type": "DRUG",
          "name": "Treatment-as-usual (Buprenorphine or Methadone)",
          "description": "Opioid agonist therapy acting as partial (buprenorphine) or full (methadone) agonists at the opioid mu receptor, provided as standard care.",
          "armGroupLabels": [
            "Treatment-as-usual (TAU)"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Qualitative themes regarding XR-NTX induction experiences and barriers",
          "description": "Themes identified through semi-structured interviews and thematic analysis to assess participant experiences with successful and unsuccessful XR-NTX induction. Key themes included readiness for change, supportive environment, caring interactions, withdrawal anxiety, ambivalence, and medication preferences.",
          "timeFrame": "Interviews conducted between July 2018 and November 2019"
        }
      ],
      "secondaryOutcomes": [],
      "otherOutcomes": []
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n* Individuals with moderate or severe opioid use disorder (OUD)\n* HIV viral RNA level of â‰¥ 200 copies/ml\n* Randomized to extended-release naltrexone (XR-NTX) in the CHOICES Scale Up Study\n* Recruited during scheduled clinic appointments for MOUD, HIV care, or study visits",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "N/A",
      "maximumAge": "N/A",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ],
      "studyPopulation": "Participants with HIV and OUD randomized to XR-NTX in five participating HIV clinics between 2018 and 2019.",
      "samplingMethod": "NON_PROBABILITY_SAMPLE"
    }
  }
}